Harvard University lawyers rejected the Trump administration’s demand to change the school’s leadership, student disciplinary policies, admissions and hiring, and end diversity, equity, and inclusion practices.
The American Association for Cancer Research will honor the following cancer researchers and physician-scientists during the AACR Annual Meeting 2025, to be held April 25-30 at the McCormick Place Convention Center in Chicago.
Hope S. Rugo has joined City of Hope to lead its Women’s Cancers Program throughout the organization and breast medical oncology division section.
USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has opened Keck Medicine of USC–Newport Beach Radiation Oncology and Imaging, a new radiation oncology and imaging center, at 4590 MacArthur Blvd. in Newport Beach, CA.
In the documentary short, “1001 cuts,” Sarah Temkin, a gynecologic oncologist, examines the enduring misogyny of medicine, particularly in the operating room.
The American College of Radiology released a statement in response to the recent paper, “Projected Lifetime Cancer Risks From Current Computed Tomography Imaging,” published in JAMA Internal Medicine.
Most patients who enroll in the Lung-MAP precision medicine trial in non-small cell lung cancer can now be matched to a targeted investigational treatment based on the results of their prior genomic testing, without needing to submit new tumor or blood samples.
Rates of colorectal cancer diagnoses dropped during and shortly after Hurricanes Irma and Maria and the COVID-19 pandemic in Puerto Rico, according to a recent analysis led by investigators at the University of Puerto Rico.
Physicians at Tampa General Hospital and USF Health Morsani College of Medicine conducted a multicenter, retrospective cohort study and found that a highly specialized treatment—heated intraperitoneal chemotherapy delivered directly into the abdominal cavity, is associated with longer survival for women with metastatic epithelial ovarian cancer.
Faron Pharmaceuticals Ltd. on April 14 announced positive topline results of the BEXMAB trial, which shows a high overall response rate among both frontline as well as relapsed/refractory high-risk myelodysplastic syndromes patients treated with a combination of bexmarilimab and azacitidine.
